MIR505, microRNA 505, 574508

N. diseases: 65; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.050 Biomarker phenotype BEFREE Collectively, the data revealed the novel role and target of miR‑505 in NSCLC cells, which may provide novel insights regarding its role in the carcinogenesis of NSCLC and its potential values for clinical applications. 30628663 2019
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.050 Biomarker phenotype BEFREE In conclusion, the present study revealed the inhibitory effects of miR‑505 on PCa tumorigenesis, which potentially occur by targeting NRCAM. 31322225 2019
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.050 Biomarker phenotype BEFREE Here, we found that miR-505 inhibited tumorigenesis as a tumor suppressor in glioblastoma. 29906532 2018
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.050 Biomarker phenotype BEFREE For example, miR-505 plays important roles in human carcinogenesis; however, its exact function in osteosarcoma remains unclear. 29251324 2018
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.050 AlteredExpression phenotype BEFREE Many miRNAs found in luminal tumors are expressed during normal mammary development. miR-135b, miR-505 and miR-155 are expressed in both basal human and mouse mammary tumors and many basal-associated miRNAs have not been previously characterized. miRNAs associated with the initiating oncogenic event driving tumorigenesis were also identified. miR-10b, -148a, -150, -199a and -486 were only expressed in normal mammary epithelium and not tumors, suggesting that they may have tumor suppressor activities. 21846369 2011